Trending: AstraZeneca Gets Green Light for Cancer Treatment in US
June 01 2023 - 06:17AM
Dow Jones News
0947 GMT - AstraZeneca is among the most mentioned companies
across news items over the past six hours, according to Factiva
data. The Anglo-Swedish company said the U.S. drug regulator
approved its drug Lynparza as a prostate cancer treatment, and also
that it has decided to discontinue the development of another drug
for inflammatory bowel disease. Lynparza was approved for the
treatment of metastatic castration-resistant prostate cancer after
success in a phase-3 trial. The treatment will be administered in
combination with abiraterone and prednisone, the company said.
Separately, AstraZeneca said it has discontinued the development of
monoclonal antibody brazikumab for the treatment of inflammatory
bowel disease, citing the competitive landscape in drug
development. Dow Jones & Co. owns Factiva.
(cecilia.butini@wsj.com)
(END) Dow Jones Newswires
June 01, 2023 06:02 ET (10:02 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Oct 2023 to Nov 2023
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Nov 2022 to Nov 2023
